St. Jude Medical First to Receive CE Mark Approval of Deep Brain Stimulation Systems for Both Primary and Secondary Dystonia

St. Jude Medical, Inc.

, a global medical device company, today announced European CE Mark approval of its Brio^™, Libra^™ and LibraXP^™ deep brain stimulation (DBS) systems for managing the symptoms of intractable primary and secondary dystonia, a neurological movement disorder that causes a person's muscles to contract and involuntarily spasm, reducing the ability to control movement. This approval represents the first by a regulatory agency for the use of deep brain stimulation to manage both primary and secondary dystonia. St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its Brio(TM), Libra(TM) and LibraXP(TM) deep brain stimulation (DBS) systems for managing the symptoms of intractable primary and secondary dystonia. (Photo: St. Jude Medical, Inc.) “Dystonia strikes people of all ages including children and young adults, often leaving them disabled and sometimes wheelchair-bound,” said Elena Moro, Ph.D., professor of neurology at the University Hospital Center of Grenoble, France. “For patients who do not respond to medications, deep brain stimulation therapy may alleviate symptoms such as repetitive, twisting movements, allowing them to improve their independence and overall quality of life.” DBS therapy for dystonia involves the delivery of mild electrical pulses to a specific target in the brain. Stimulation is delivered to one of two regions, the subthalamic nucleus (STN) or the globus pallidus interna (GPi), areas of the brain involved with controlling movement. Irregular nerve signals responsible for some of the disabling symptoms are stimulated by DBS therapy, ultimately helping the patient improve movement.